Proguanil synergistically sensitizes ovarian cancer cells to olaparib by increasing DNA damage and inducing apoptosis

Ovarian cancer is the second leading cause of cancer-related deaths in women, with low five-year survival rates. Therefore, it is essential to seek new treatment options. Olaparib, a PARP inhibitor, has benefited many ovarian cancer patients, but olaparib is much less effective as a single agent in...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Yan, Wu, Tianyu, Hu, Xin, Xu, Simeng, Xiao, Di, Wu, Jingtao, Yan, Xinjian, Yang, Xiaoping, Li, Gaofeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2022
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8795793/
https://www.ncbi.nlm.nih.gov/pubmed/35165509
http://dx.doi.org/10.7150/ijms.67027

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8795793/
https://www.ncbi.nlm.nih.gov/pubmed/35165509
http://dx.doi.org/10.7150/ijms.67027

Ejemplares similares